Thrombolysis for pulmonary embolism: Past, present and future
Key result
Thrombolysis reduces in-hospital death or recurrence in high-risk pulmonary embolism, while its optimal use in intermediate-risk patients remains controversial pending ongoing trials.
Why the study?
Does thrombolytic treatment reduce in-hospital death or PE recurrence in patients with pulmonary embolism?
Population
Patients with pulmonary embolism, including high-risk, intermediate-risk, and non-high-risk patients.
Comparison
Thrombolytic treatment vs Heparin anticoagulation or surgery
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Affirms thrombolysis for high-risk PE; leaves intermediate-risk selection unresolved pending ongoing trials.
Structured PICO
Does thrombolytic treatment reduce in-hospital death or PE recurrence in patients with pulmonary embolism?
P
Population
Patients with pulmonary embolism (PE), including high-risk (shock or hypotension), intermediate-risk (normotensive with right ventricular dysfunction or elevated cardiac biomarkers), and non-high-risk patients.
I
Intervention
Thrombolytic treatment
C
Comparator
Heparin anticoagulation or surgery
O
Outcome
In-hospital death or PE recurrencehard clinical
Thrombolysis is strongly indicated for high-risk pulmonary embolism, while its use in intermediate-risk patients remains controversial pending ongoing trial results.
Cite This Study
Lankeit et al. (2010) conducted a review in Pulmonary embolism. Thrombolysis was evaluated. Thrombolysis reduces in-hospital death or recurrence in high-risk pulmonary embolism, while its optimal use in intermediate-risk patients remains controversial pending ongoing trials.